SCHEMBL2174600

SCHEMBL2174600

COC(=O)c1ccc(S(=O)(=O)Nc2cccc(Cl)c2C)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.61
LMNA P02545 4/20 0.58
SMN1; SMN2 Q16637 4/20 0.55
CYP2C9 P11712 5/20 0.54
MAPT P10636 5/20 0.53
POLB P06746 1/20 0.53
ALDH1A1 P00352 5/20 0.52
TSHR P16473 3/20 0.52
NPSR1 Q6W5P4 1/20 0.52
KDM4E B2RXH2 2/20 0.52
HTT P42858 2/20 0.52
MEN1 O00255 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
HPGD P15428 1/20 0.52
CRHBP P24387 1/20 0.52
CYP2C19 P33261 1/20 0.52
KMT2A Q03164 1/20 0.52
CRHR2 Q13324 1/20 0.52
NOD2 Q9HC29 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12406979 0.87 KDM4E (0.60) FFAR4LMNASMN1; SMN2CYP2C9MAPT
SCHEMBL2178383 0.86 KDM4E (0.58) FFAR4LMNAMAPTPOLBALDH1A1
SCHEMBL12406983 0.86 ALDH1A1 (0.55) FFAR4LMNASMN1; SMN2MAPTPOLB
SCHEMBL2176669 0.82 LMNA (0.61) FFAR4LMNASMN1; SMN2CYP2C9MAPT
SCHEMBL12407072 0.80 MAPT (0.54) FFAR4LMNASMN1; SMN2MAPTPOLB
SCHEMBL2175966 0.79 TSHR (0.72) LMNAMAPTPOLBALDH1A1TSHR
SCHEMBL29957626 0.78 MAPT (0.53) FFAR4LMNAMAPTPOLBALDH1A1
SCHEMBL2175745 0.78 MAPT (0.53) FFAR4LMNAMAPTPOLBALDH1A1
SCHEMBL6542410 0.78 SLC40A1 (0.59) FFAR4LMNASMN1; SMN2CYP2C9MAPT
SCHEMBL12407078 0.78 FFAR4 (0.55) FFAR4LMNAMAPTPOLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050446-B1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-05-07 EP disclosed
EP-2050446-B1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-05-07 EP disclosed
US-7973078-B2 Sulfonamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2011-07-05 US disclosed
US-7973078-B2 Sulfonamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2011-07-05 US disclosed
US-7973078-B2 Sulfonamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2011-07-05 US disclosed
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-12-17 US disclosed
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-12-17 US disclosed
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-12-17 US disclosed
EP-2050446-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF PTGER1, CYSLTR1, PTGER2 FFAR4 408/4885LMNA 4123/4885SMN1; SMN2 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.